Ser942
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.9
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser942  -  CTDP1 (human)

Site Information
ssNEDEGsssEADEM   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 455466

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 )
Disease tissue studied:
leukemia ( 2 ) , chronic myelogenous leukemia ( 2 )
Relevant cell line - cell type - tissue:
K562 (erythroid) ( 2 )

Upstream Regulation
Kinases, in vitro:
CK2A1 (human) ( 3 )

Downstream Regulation
Effects of modification on CTDP1:
enzymatic activity, induced ( 1 ) , molecular association, regulation ( 1 , 3 )
Effects of modification on biological processes:
transcription, altered ( 3 )
Induce interaction with:
GTF2F1 (human) ( 1 , 3 )

References 

1

Yang A, et al. (2009) NMR structure of a complex formed by the carboxyl-terminal domain of human RAP74 and a phosphorylated peptide from the central domain of the FCP1 phosphatase. Biochemistry 48, 1964-74
19215094   Curated Info

2

Moritz A (2007) CST Curation Set: 3528; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

3

Abbott KL, et al. (2005) Enhanced binding of RNAP II CTD phosphatase FCP1 to RAP74 following CK2 phosphorylation. Biochemistry 44, 2732-45
15723518   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.